Lysergic acid methylamide
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Lysergic acid methylamide (LAM), also known as N-methyllysergamide (NM-LA), is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug lysergic acid diethylamide (LSD).[1][2][4] It is the N-methyl derivative of ergine (lysergic acid amide; LSA) and the analogue of LSD in which the N,N-diethyl groups have been replaced with one N-methyl group.[1][2][4]
- None
| Clinical data | |
|---|---|
| Other names | Lysergic acid methylamide; LAM; Lysergic acid monomethylamide; LA-methylamide; LA-monomethylamide; N-Methyllysergamide; NM-LA; N-Methyl-LSA; N-Methylergine; N,6-Dimethyl-9,10-didehydroergoline-8β-carboxamide |
| Routes of administration | Oral[1][2][3] |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H19N3O |
| Molar mass | 281.359 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug is active in humans at a dose of approximately 500 μg and has roughly 20% of the potency of LSD as a drug.[1][2][3] However, it has been said to produce autonomic effects but to produce no psychoactive or hallucinogenic effects at this dose.[3][2][5] The drug has about 6.3% of the antiserotonergic potency of LSD in the isolated rat uterus in vitro.[4][3][6][7]
LAM was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[8][9][10][11]
See also
- Substituted lysergamide
- Lysergic acid amide (LSA; ergine)
- Lysergic acid ethylamide (LAE-32)
- Lysergic acid dimethylamide (DAM-57)